Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial

Giuseppe Derosa, Pamela Maffioli, Maria D'Avino, Carla Sala, Amedeo Mugellini, Vito Vulpis, Salvatore Felis, Luigina Guasti, Riccardo Sarzani, Alessandro Bestetti, Massimo Vanasia, Giovanni Gaudio, ESCAPE-IT Trial Investigators group, Giuseppe Derosa, Pamela Maffioli, Maria D'Avino, Carla Sala, Amedeo Mugellini, Vito Vulpis, Salvatore Felis, Luigina Guasti, Riccardo Sarzani, Alessandro Bestetti, Massimo Vanasia, Giovanni Gaudio, ESCAPE-IT Trial Investigators group

Abstract

Aim: To evaluate the effects of canrenone as add-on therapy in patients already treated with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARBs) and hydrochlorothiazide at the maximum dosage (25 mg/d).

Method: In this randomized, open-label, controlled trial, we enrolled 175 Caucasian patients with essential hypertension not well controlled by concomitant ACE-I or ARBs and hydrochlorothiazide. At baseline, 87 patients (57 males and 30 females) were randomized to add canrenone 50 mg, and 88 (56 males and 32 females) patients to canrenone 100 mg, once a day, for 3 months. At baseline and after 3 months, we evaluated blood pressure (BP), pulse pressure (PP), heart rate (HR), fasting plasma glucose (FPG), homeostasis model assessment insulin (HOMA Index), lipid profile, electrolytes, uric acid, estimated glomerular filtration rate (eGFR), plasma urea, aldosterone, B-type natriuretic peptide (BNP), and galectin-3.

Results: Blood pressure decreased with both dosages of canrenone, with a better effect with canrenone 100 mg (-20.26 vs -23.68 mm Hg for SBP, and -10.58 vs -12.38 mm Hg for DBP), without a clinically relevant increase in potassium levels. We did not observe any differences regarding FPG or HOMA Index, nor of lipid profile, with the exception of triglycerides, which increased compared to baseline with canrenone 50 mg (+0.25 vs +0.34 mEq/L). Creatinine slightly increased with canrenone 100 mg (+0.02 vs +0.05 mg/dL), although no variations of eGFR were observed in neither groups. There was an increase in aldosterone levels with canrenone 50 mg. No changes in BNP or galectin-3 were recorded.

Conclusion: Both canrenone dosages gave a decrease in blood pressure, with a better effect with the higher dose, with only a slight increase in potassium and creatinine levels, which were not clinically relevant. Clinical Trials Registration Eudract number: 2010-023606-13; ClinicalTrials.gov NCT02687178.

Keywords: Angiotensin II receptor blockers; Angiotensin-converting enzyme inhibitors; Canrenone; Hydrochlorothiazide; Hypertension.

Conflict of interest statement

Andrea Bestetti and Massimo Vanasia are employed by THERABEL GiEnne Pharma, Milano, Italy. The other authors declare that they have no conflict of interest.

© 2016 The Authors. Cardiovascular Therapeutics Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Study design
Figure 2
Figure 2
CONSORT diagram showing the flow of patients through the study

References

    1. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris). 2000;61:52–60.
    1. Hawkins UA, Gomez‐Sanchez EP, Gomez‐Sanchez CM, Gomez‐Sanchez CE. The ubiquitous mineralocorticoid receptor: clinical implications. Curr Hypertens Rep. 2012;4:573–580.
    1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.
    1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
    1. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, EMPHASIS‐HF Study Group . Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
    1. de Simone G, Chinali M, Mureddu GF, Cacciatore G, Lucci D, AREA‐in‐CHF Investigators . Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA‐in‐CHF study. Nutr Metab Cardiovasc Dis. 2011;21:783–791.
    1. European Diabetes Policy Group . A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999;16:716–730.
    1. Heding LG. Determination of total serum insulin (IRI) in insulin‐treated diabetic patients. Diabetologia. 1972;8:260–266.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
    1. Klose S, Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem greiner selective analyzer (GSA II). J Clin Chem Clin Biochem. 1978;15:121–130.
    1. Wahlefeld AW. Methods of Enzymatic Analysis: Triglycerides Determination After Enzymatic Hydrolysis. 2nd English ed New York: Academic Press, Inc; 1974:18–31.
    1. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345–1353.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    1. New JP, O'Donoghue DJ, Middleton RJ, et al. Time to move from serum creatinine to eGFR. Diabet Med. 2006;23:1047–1049.
    1. Boccanelli A, Cacciatore G, Mureddu GF, et al. Baseline characteristics of patients recruited in the AREA IN‐CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). J Cardiovasc Med (Hagerstown). 2007;8:683–691.
    1. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin‐3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL‐HF study. Clin Res Cardiol. 2010;99:323–328.
    1. Winer BJ. Statistical Principles in Experimental Design, 2nd edn New York: McGraw‐Hill; 1971.
    1. Fogari R, Derosa G, Zoppi A, Lazzari P, D'Angelo A, Mugellini A. Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well‐controlled type 2 diabetic hypertensive patients with microalbuminuria. Expert Opin Pharmacother. 2014;15:453–459.
    1. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094–2102.
    1. Václavík J, Sedlák R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) a randomized, double‐blind, placebo‐controlled trial. Hypertension. 2011;57:1069–1075.
    1. Derosa G, Bonaventura A, Bianchi L, et al. Effects of canrenone in patients with metabolic syndrome. Expert Opin Pharmacother. 2013;14:2161–2169.
    1. Derosa G, Romano D, Bianchi L, D'Angelo A, Maffioli P. The effects of canrenone on inflammatory markers in patients with metabolic syndrome. Ann Med. 2015;47:47–52.
    1. Li LC, Li J, Gao J. Functions of galectin‐3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014;351:336–343.
    1. Vergaro G, Prud'homme M, Fazal L, et al. Inhibition of galectin‐3 pathway prevents isoproterenol‐induced left ventricular dysfunction and fibrosis in mice. Hypertension 2016;67:606–612.
    1. Xu Z, Li X, Huang Y, et al. The predictive value of plasma galectin‐3 for ARDS severity and clinical outcome. Shock. 2016. doi: 10.1097/SHK.0000000000000757.
    1. Yang L, Zhang H, Cai M, et al. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens. 2016;38:464–468.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する